Portal de Periódicos da CAPES

Effect of Basal Insulin Glargine on First and Recurrent Episodes of Heart Failure Hospitalization

2017; Lippincott Williams & Wilkins; Volume: 137; Issue: 1 Linguagem: Inglês

10.1161/circulationaha.117.030924

1524-4539

Hertzel C. Gerstein, Hye Jung Jung, Lars Rydén, Rafael Díaz, Richard E. Gilbert, Salim Yusuf,

Diabetes Management and Research

HomeCirculationVol. 137, No. 1Effect of Basal Insulin Glargine on First and Recurrent Episodes of Heart Failure Hospitalization Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessLetterPDF/EPUBEffect of Basal Insulin Glargine on First and Recurrent Episodes of Heart Failure HospitalizationThe ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention) Hertzel C. Gerstein, MD, MSc, Hyejung Jung, MSc, Lars Rydén, MD, PhD, Rafael Diaz, MD, Richard E. Gilbert, MBBS, PhD and Salim Yusuf, DPhilOn behalf of the ORIGIN Investigators Hertzel C. GersteinHertzel C. Gerstein Population Health Research Institute, McMaster University and Hamilton Health Sciences, Ontario, Canada (H.C.G., H.J., S.Y.) , Hyejung JungHyejung Jung Population Health Research Institute, McMaster University and Hamilton Health Sciences, Ontario, Canada (H.C.G., H.J., S.Y.) , Lars RydénLars Rydén Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden (L.R.) , Rafael DiazRafael Diaz Estudios Clínicos Latino América, Rosario, Argentina (R.D.) , Richard E. GilbertRichard E. Gilbert St Michael's Hospital, University of Toronto, Ontario, Canada (R.E.G.). and Salim YusufSalim Yusuf Population Health Research Institute, McMaster University and Hamilton Health Sciences, Ontario, Canada (H.C.G., H.J., S.Y.) and On behalf of the ORIGIN Investigators Originally published2 Jan 2018https://doi.org/10.1161/CIRCULATIONAHA.117.030924Circulation. 2018;137:88–90Diabetes mellitus increases the incidence of recurrent heart failure through a variety of potential mechanisms, including ischemic myocardial damage, hyperglycemia, and the effects of the glucose-linked metabolic abnormalities on the myocardium.1 To date, randomized controlled trials of more versus less glucose lowering with a menu of drugs, including insulin, have reported a neutral effect on incident heart failure. Nevertheless, epidemiological studies and the sodium-retaining properties of insulin have fueled concerns about a possible link.2The ORIGIN trial (Outcome Reduction With Initial Glargine Intervention) allocated 12 537 people (mean age, 64 years; 35% women) with diabetes mellitus (88%), impaired glucose tolerance, or impaired fasting glucose to either basal insulin-mediated normoglycemia or therapy without insulin and reported a neutral effect on cardiovascular events during a median follow-up of 6.2 years. People with New York Heart Association class 3 or 4 heart failure were excluded. Heart failure requiring hospitalization was a prespecified component of the primary outcome and was defined as evidence of overnight hospitalization or attendance in an acute care setting for at least 2 of the following: signs or symptoms of heart failure; radiological evidence of congestive heart failure; treated with intravenous diuretics, or a first or increased dose of an oral diuretic, intravenous or oral vasodilator, or intravenous or oral inotrope.3 Both first and recurrent episodes were prospectively collected and blindly adjudicated; however, only analyses of the first heart failure hospitalization were prespecified. The trial was approved by local ethics committees at all sites, and all participants signed informed consent.Cox regression was used to estimate the hazard of allocation to insulin glargine on the first heart failure hospitalization before and after accounting for the competing risk of death. It was also used to estimate the hazard of recurrent episodes in 2 ways. First, after adjustment for the competing risk of death, a joint frailty model was used that accounts for the multiplicity of events, the likelihood that a person who has had 1 event will have another, and the competing risk of death. Second, a proportional means model (an extension of the Cox model for the analyses of recurrent events) was used to estimate the hazard ratio.4 In addition, the effect of glargine allocation on recurrent events was estimated by calculating an event rate ratio with a Poisson model5 and by using the more conservative negative binomial model, which additionally accounts for the heterogeneity of each participant's risk of recurrent events. P values were not adjusted for multiple comparisons. All statistical analyses were done with SAS version 9.4 (SAS Institute Inc, Cary, NC).There was a high contrast in insulin use during the trial at both 2 years (89.7% and 3.5% of glargine and standard care participants, respectively) and 6 years (83.6% and 10.0%, respectively). During follow-up, the percentage of the 1916 deaths (2.6%/y) and 653 first heart failure hospitalizations (0.9%/y) did not differ by allocated treatment, whereas the 223 second heart failure hospitalizations (0.3%/y) occurred less frequently in participants allocated to insulin glargine compared with standard care (0.25%/y and 0.35%/y, respectively; P=0.01). Allocation to insulin glargine had a neutral effect (log-rank P=0.19) on the occurrence of at least 1 hospitalization for heart failure before (hazard ratio, 0.90; 95% confidence interval, 0.77–1.05)3 and after (hazard ratio, 0.90; 95% confidence interval, 0.77–1.05; P=0.19) accounting for the competing risk of death. Additional analyses with 4 different models (Figure) showed that allocation to insulin glargine generally had a neutral effect on recurrent events.Download figureDownload PowerPointFigure. Risk of death and heart failure hospitalizations (HFHs). The effects of allocation to glargine on death, the composite of death or HFH, HFH accounting for the competing risk of death, and recurrent episodes of HFH using different methods are depicted as hazard ratios or, for the Poisson and negative binomial models, event rate ratios. The proportional means, Poisson, and negative binomial models do not account for the competing risk of death. CI indicates confidence interval.These ORIGIN trial intention-to-treat analyses show that insulin glargine has a neutral effect on both initial and recurrent heart failure hospitalizations. They suggest that previous reports from observational studies linking insulin use to heart failure may have been affected by confounding of insulin use with other factors linked to a poor prognosis. The fact that ORIGIN participants were randomly allocated to either insulin or no insulin effectively deals with this possibility.These findings are limited by the fact that information on history of New York Heart Association class 1 or 2 heart failure status was not collected. Nevertheless, the very large sample size provides reassurance that baseline history of heart failure was distributed equally across the treatment groups and that any postrandomization difference reflects the effect of the intervention. It is also limited by the inclusion of only those heart failure episodes serious enough to require hospitalization. Conversely, the high retention, adherence, and between-group differences in insulin use; adjustment for the competing risk of death; number of episodes; long follow-up; and blind adjudication of all heart failure hospitalizations are clear strengths. Overall, these findings are clearly reassuring for people using or considering the use of insulin and are relevant to future research into the effect of insulin on this serious and common cardiovascular outcome in people with diabetes mellitus.Hertzel C. Gerstein, MD, MScHyejung Jung, MScLars Rydén, MD, PhDRafael Diaz, MDRichard E. Gilbert, MBBS, PhDSalim Yusuf, DPhilOn behalf of the ORIGIN InvestigatorsSources of FundingThe ORIGIN trial was funded by Sanofi.DisclosuresDr Gerstein is supported by the McMaster-Sanofi Population Health Institute Chair in Diabetes Research and Care. Dr Gerstein has received research grant support from Sanofi, Lilly, AstraZeneca, and Merck; honoraria for speaking from Sanofi, Novo Nordisk, AstraZeneca, and Berlin Chemie; and consulting fees from Sanofi, Lilly, AstraZeneca, Merck, Novo Nordisk, Abbot, Amgen, Boehringer Ingelheim, and Kaneq Bioscience. Hyejung Jung is an employee of the Population Health Research Institute. Dr Rydén reports research grants from the Swedish Heart-Lung Foundation, the Swedish Diabetes Foundation, the European Society of Cardiology, Amgen, Bayer Health Care, Boehringer-Ingelheim, Merck, and Novo Nordisk; honoraria for speaking from Boehringer-Ingelheim, Merck, Novo-Nordisk, and Sanofi-Aventis; and consulting fees from Boehringer-Ingelheim, Merck, and Novo Nordisk. Dr Diaz has received research grant support from Sanofi. Dr Gilbert has received consulting and lecture fees along with grant funds through his institution from Merck, AstraZeneca, Eli Lilly, Boehringer Ingelheim, and Janssen. Dr Gilbert is the Canada Research Chair in Diabetes Complications, and this review was supported in part by the Canada Research Chair Program. Dr Yusuf has received research grant support from Sanofi related to the ORIGIN trial.FootnotesClinical Trial Registration (URL: https://www.clinicaltrials.gov. Unique identifier: NCT00069784).Circulation is available at http://circ.ahajournals.org.Correspondence to: Hertzel C. Gerstein, MD, MSc, HSC 3V38, 1280 Main Street West, Hamilton, Ontario, L8S4K1 Canada. E-mail [email protected]References1. McMurray JJ, Gerstein HC, Holman RR, Pfeffer MA. Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored.Lancet Diabetes Endocrinol. 2014; 2:843–851. doi: 10.1016/S2213-8587(14)70031-2.CrossrefMedlineGoogle Scholar2. Gilbert RE, Krum H. Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy.Lancet. 2015; 385:2107–2117. doi: 10.1016/S0140-6736(14)61402-1.CrossrefMedlineGoogle Scholar3. Gerstein HC, Bosch J, Dagenais GR, Diaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Ryden LE, Yusuf S. Basal insulin and cardiovascular and other outcomes in dysglycemia.N Engl J Med. 2012; 367:319–328. doi: 10.1056/NEJMoa1203858.CrossrefMedlineGoogle Scholar4. Lin DY, Wei LJ, Yang I, Ying Z. Semiparametric regression for the mean and rate functions of recurrent events.J Royal Stat Soc B. 2000; 62:711–730. doi: 10.1111/1467-9868.00259.CrossrefGoogle Scholar5. Glynn RJ, Buring JE. Ways of measuring rates of recurrent events.BMJ. 1996; 312:364–367. doi: 10.1136/bmj.312.7027.364.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By McDonagh T, Metra M, Adamo M, Gardner R, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland J, Coats A, Crespo-Leiro M, Farmakis D, Gilard M, Heyman S, Hoes A, Jaarsma T, Jankowska E, Lainscak M, Lam C, Lyon A, McMurray J, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano G, Ruschitzka F and Skibelund A (2022) Guía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica, Revista Española de Cardiología, 10.1016/j.recesp.2021.11.027, 75:6, (523.e1-523.e114), Online publication date: 1-Jun-2022. Shao H, Kianmehr H, Guo J, Li P, Fonseca V and Shi L (2022) Efficacy of iGlarLixi on 5-year risk of diabetes-related complications: A simulation study, Journal of Diabetes and its Complications, 10.1016/j.jdiacomp.2022.108132, 36:3, (108132), Online publication date: 1-Mar-2022. McDonagh T, Metra M, Adamo M, Gardner R, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland J, Coats A, Crespo‐Leiro M, Farmakis D, Gilard M, Heymans S, Hoes A, Jaarsma T, Jankowska E, Lainscak M, Lam C, Lyon A, McMurray J, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano G, Ruschitzka F, Kathrine Skibelund A, de Boer R, Christian Schulze P, Abdelhamid M, Aboyans V, Adamopoulos S, Anker S, Arbelo E, Asteggiano R, Bauersachs J, Bayes‐Genis A, Borger M, Budts W, Cikes M, Damman K, Delgado V, Dendale P, Dilaveris P, Drexel H, Ezekowitz J, Falk V, Fauchier L, Filippatos G, Fraser A, Frey N, Gale C, Gustafsson F, Harris J, Iung B, Janssens S, Jessup M, Konradi A, Kotecha D, Lambrinou E, Lancellotti P, Landmesser U, Leclercq C, Lewis B, Leyva F, Linhart A, Løchen M, Lund L, Mancini D, Masip J, Milicic D, Mueller C, Nef H, Nielsen J, Neubeck L, Noutsias M, Petersen S, Sonia Petronio A, Ponikowski P, Prescott E, Rakisheva A, Richter D, Schlyakhto E, Seferovic P, Senni M, Sitges M, Sousa‐Uva M, Tocchetti C, Touyz R, Tschoepe C and Waltenberger J (2022) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure, European Journal of Heart Failure, 10.1002/ejhf.2333, 24:1, (4-131), Online publication date: 1-Jan-2022. McDonagh T, Metra M, Adamo M, Gardner R, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland J, Coats A, Crespo-Leiro M, Farmakis D, Gilard M, Heymans S, Hoes A, Jaarsma T, Jankowska E, Lainscak M, Lam C, Lyon A, McMurray J, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano G, Ruschitzka F, Kathrine Skibelund A, de Boer R, Christian Schulze P, Abdelhamid M, Aboyans V, Adamopoulos S, Anker S, Arbelo E, Asteggiano R, Bauersachs J, Bayes-Genis A, Borger M, Budts W, Cikes M, Damman K, Delgado V, Dendale P, Dilaveris P, Drexel H, Ezekowitz J, Falk V, Fauchier L, Filippatos G, Fraser A, Frey N, Gale C, Gustafsson F, Harris J, Iung B, Janssens S, Jessup M, Konradi A, Kotecha D, Lambrinou E, Lancellotti P, Landmesser U, Leclercq C, Lewis B, Leyva F, Linhart A, Løchen M, Lund L, Mancini D, Masip J, Milicic D, Mueller C, Nef H, Nielsen J, Neubeck L, Noutsias M, Petersen S, Sonia Petronio A, Ponikowski P, Prescott E, Rakisheva A, Richter D, Schlyakhto E, Seferovic P, Senni M, Sitges M, Sousa-Uva M, Tocchetti C, Touyz R, Tschoepe C, Waltenberger J, Adamo M, Baumbach A, Böhm M, Burri H, Čelutkienė J, Chioncel O, Cleland J, Coats A, Crespo-Leiro M, Farmakis D, Gardner R, Gilard M, Heymans S, Hoes A, Jaarsma T, Jankowska E, Lainscak M, Lam C, Lyon A, McMurray J, Mebazaa A, Mindham R, Muneretto C, Piepoli M, Price S, Rosano G, Ruschitzka F and Skibelund A (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure, European Heart Journal, 10.1093/eurheartj/ehab368, 42:36, (3599-3726), Online publication date: 21-Sep-2021. Lambadiari V, Thymis J, Kouretas D, Skaperda Z, Tekos F, Kousathana F, Kountouri A, Balampanis K, Parissis J, Andreadou I, Tsoumani M, Chania C, Katogiannis K, Dimitriadis G, Bamias A and Ikonomidis I (2021) Effects of a 12-Month Treatment with Glucagon-like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Oxidant and Antioxidant Biomarkers in Patients with Type 2 Diabetes, Antioxidants, 10.3390/antiox10091379, 10:9, (1379) Avogaro A, Barillà F, Cavalot F, Consoli A, Federici M, Mancone M, Paolillo S, Pedrinelli R, Perseghin G, Perrone Filardi P, Scicali R, Sinagra G, Spaccarotella C, Indolfi C and Purrello F (2021) Cardiovascular risk management in type 2 diabetes mellitus: A joint position paper of the Italian Cardiology (SIC) and Italian Diabetes (SID) Societies, Nutrition, Metabolism and Cardiovascular Diseases, 10.1016/j.numecd.2021.02.029, 31:6, (1671-1690), Online publication date: 1-Jun-2021. Shen J and Greenberg B (2021) Diabetes Management in Patients with Heart Failure, Diabetes & Metabolism Journal, 10.4093/dmj.2020.0296, 45:2, (158-172), Online publication date: 31-Mar-2021. Sohrabi C, Saberwal B, Lim W, Tousoulis D, Ahsan S and Papageorgiou N Heart Failure in Diabetes Mellitus: An Updated Review, Current Pharmaceutical Design, 10.2174/1381612826666201118091659, 26:46, (5933-5952) Bertoluci M, Salles J, Silva-Nunes J, Pedrosa H, Moreira R, da Silva Duarte R, da Costa Carvalho D, Trujilho F, dos Santos Raposo J, Parente E, Valente F, de Moura F, Hohl A, Melo M, Araujo F, de Araújo Principe R, Kupfer R, Costa e Forti A, Valerio C, Ferreira H, Duarte J, Saraiva J, Rodacki M, Castelo M, Monteiro M, Branco P, de Matos P, de Melo Pereira de Magalhães P, Betti R, Réa R, Trujilho T, Pinto L and Leitão C (2020) Portuguese-Brazilian evidence-based guideline on the management of hyperglycemia in type 2 diabetes mellitus, Diabetology & Metabolic Syndrome, 10.1186/s13098-020-00551-1, 12:1, Online publication date: 1-Dec-2020. Mehta A, Bhattacharya S, Estep J and Faiman C (2020) Diabetes and Heart Failure, Clinics in Geriatric Medicine, 10.1016/j.cger.2020.04.005, 36:3, (447-455), Online publication date: 1-Aug-2020. Hanefeld M, Fleischmann H, Siegmund T and Seufert J (2020) Rationale for Timely Insulin Therapy in Type 2 Diabetes Within the Framework of Individualised Treatment: 2020 Update, Diabetes Therapy, 10.1007/s13300-020-00855-5, 11:8, (1645-1666), Online publication date: 1-Aug-2020. Ikonomidis I, Pavlidis G, Thymis J, Birba D, Kalogeris A, Kousathana F, Kountouri A, Balampanis K, Parissis J, Andreadou I, Katogiannis K, Dimitriadis G, Bamias A, Iliodromitis E and Lambadiari V (2020) Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment, Journal of the American Heart Association, 9:9, Online publication date: 5-May-2020. (2020) Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction, New England Journal of Medicine, 10.1056/NEJMc1917241, 382:10, (972-973), Online publication date: 5-Mar-2020. Wiggers H (2019) Insulin treatment in heart failure patients: the good, the bad or the ugly?, European Journal of Heart Failure, 10.1002/ejhf.1556, 21:8, (985-987), Online publication date: 1-Aug-2019. Shen L, Rørth R, Cosmi D, Kristensen S, Petrie M, Cosmi F, Latini R, Køber L, Anand I, Carson P, Granger C, Komajda M, McKelvie R, Solomon S, Staszewsky L, Swedberg K, Huynh T, Zile M, Jhund P and McMurray J (2019) Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction, European Journal of Heart Failure, 10.1002/ejhf.1535, 21:8, (974-984), Online publication date: 1-Aug-2019. Bell D and Goncalves E (2019) Heart failure in the patient with diabetes: Epidemiology, aetiology, prognosis, therapy and the effect of glucose‐lowering medications, Diabetes, Obesity and Metabolism, 10.1111/dom.13652, 21:6, (1277-1290), Online publication date: 1-Jun-2019. Kenny H and Abel E (2019) Heart Failure in Type 2 Diabetes Mellitus, Circulation Research, 124:1, (121-141), Online publication date: 4-Jan-2019. Carbone S, Dixon D, Buckley L and Abbate A (2018) Glucose-Lowering Therapies for Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: State-of-the-Art Review, Mayo Clinic Proceedings, 10.1016/j.mayocp.2018.07.018, 93:11, (1629-1647), Online publication date: 1-Nov-2018. Bassi N and Fonarow G (2018) Prevention of Heart Failure in Patients with Diabetes: Role of Diabetes Medications, Current Cardiology Reports, 10.1007/s11886-018-1050-3, 20:11, Online publication date: 1-Nov-2018. Rørth R, Jhund P, Mogensen U, Kristensen S, Petrie M, Køber L and McMurray J (2018) Risk of Incident Heart Failure in Patients With Diabetes and Asymptomatic Left Ventricular Systolic Dysfunction, Diabetes Care, 10.2337/dc17-2583, 41:6, (1285-1291), Online publication date: 1-Jun-2018. January 2, 2018Vol 137, Issue 1 Advertisement Article InformationMetrics © 2018 American Heart Association, Inc.https://doi.org/10.1161/CIRCULATIONAHA.117.030924PMID: 29279340 Originally publishedJanuary 2, 2018 Keywordsinsulin glargineheart failurehospitalizationPDF download Advertisement SubjectsCardiovascular DiseaseDiabetes, Type 2EpidemiologyHeart FailureRisk Factors